Abstract
There remains widespread doubt among clinicians that mere lifestyle advice and counseling provided in routine care can achieve improvements in health. We aimed to determine the health effects of the largest behavior change program for pre-diabetes globally (the English Diabetes Prevention Programme) when implemented at scale in routine care. We exploited the threshold in glycated hemoglobin (HbA1c) used to decide on program eligibility by applying a regression discontinuity design, one of the most credible quasi-experimental strategies for causal inference, to electronic health data from approximately one-fifth of all primary care practices in England. Program referral led to significant improvements in patients’ HbA1c and body mass index. This analysis provides causal, rather than associational, evidence that lifestyle advice and counseling implemented in a national health system can achieve important health improvements.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Institute of Allergy and Infectious Diseases (1DP2AI171011; PG) Chan Zuckerberg Biohub investigator award (PG) Alexander von Humboldt Foundation Alexander von Humboldt Professor award (TB) Ministry of Science, Research, and the Arts Baden-Wuerttemberg (MWK), Germany, German Research Foundation (DFG), the state of Baden-Wuerttemberg, Germany, and the German Research Foundation (DFG) grant INST 35/1314-1 FUGG (as part of data storage and computing resources)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The CPRD has been granted generic ethics approval for observational studies that make use of only anonymised data and linked anonymised NHS health-care data (Multiple Research Ethics Committee ref. 05/MRE04/87). The CPRD Independent Scientific Advisory Committee approved the study protocol (20_000052) in accordance with the Declaration of Helsinki. This analysis of pseudonymized data (ie, data that could not be linked to individuals without additional information that was not available to the analysts) is considered exempt for nonhuman subjects research by the institutional review board of the Heidelberg University Medical Faculty.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from Clinical Practice Research Datalink, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Due to Clinical Practice Research Datalink license restrictions, we are unable to share data.
